Eur J Cancer
-
Publication Venue For
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.. 185:178-215. 2023
- Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.. 174:142-152. 2022
- Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.. 172:367-386. 2022
- De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.. 171:55-63. 2022
- Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.. 170:296-304. 2022
- Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.. 170:285-295. 2022
- Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.. 160:24-60. 2022
- Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.. 160:61-71. 2022
- Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.. 155:216-226. 2021
- Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. 150:83-94. 2021
- Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival.. 136:84-94. 2020
- Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.. 133:4-13. 2020
- The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.. 127:96-107. 2020
- DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.. 123:48-57. 2019
- Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.. 123:101-111. 2019
- Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.. 117:91-98. 2019
- Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.. 114:128-136. 2019
- Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).. 112:66-79. 2019
- Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.. 111:82-93. 2019
- Volume effect in paediatric brain tumour resection surgery: analysis of data from the Japanese national inpatient database.. 109:111-119. 2019
- Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.. 106:133-143. 2019
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.. 107:142-152. 2019
- Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study.. 106:171-180. 2019
- Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].. 103:287. 2018
- Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.. 101:114-122. 2018
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.. 94:115-125. 2018
- Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.. 86:37-45. 2017
- Apoptotic capacity and risk of squamous cell carcinoma of the head and neck.. 72:166-176. 2017
- Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.. 67:46-54. 2016
- Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.. 61:94-101. 2016
- Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.. 52:1-9. 2016
- The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients.. 51:2808-2819. 2015
- (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.. 51:1857-1864. 2015
- A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.. 51:1714-1724. 2015
- Duration of Trastuzumab. In matters of the heart, one size may not fit all?. 51:1657-1659. 2015
- Unmet needs and depression among carers of people newly diagnosed with cancer.. 51:2049-2057. 2015
- Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.. 51:1978-1988. 2015
- A functional variant at miRNA-122 binding site in IL-1α 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer.. 51:1415-1423. 2015
- Development and external validation of nomograms predictive of response to radiation therapy and overall survival in nasopharyngeal cancer patients.. 51:1303-1311. 2015
- Are we ready to predict late effects? A systematic review of clinically useful prediction models.. 51:758-766. 2015
- Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.. 50:2544-2549. 2014
- Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.. 50:1706-1716. 2014
- Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α.. 50:1531-1540. 2014
- Functional single nucleotide polymorphisms of the RASSF3 gene and susceptibility to squamous cell carcinoma of the head and neck.. 50:582-592. 2014
- Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.. 49:3149-3158. 2013
- Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.. 49:2949-2959. 2013
- What really matters in cancer?: Putting people back into the heart of cancer policy.. 49:1669-1672. 2013
- Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium.. 49:1335-1345. 2013
- Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.. 47:683-689. 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.. 47:8-32. 2011
- Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma.. 47:107-115. 2011
- Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.. 46:1132-1143. 2010
- The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.. 46:517-525. 2010
- Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.. 45:608-617. 2009
- Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.. 44:2319-2329. 2008
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. 2017
- Does time of day of radiation therapy affect treatment outcome? The circadian/melatonin hypothesis